Biocon (NSE:BIOCON) Cyclically Adjusted PB Ratio: (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BIOCON Biocon Ltd NSE:BIOCON
92 GF Score
Price ₹392.30
GF Value ₹332.55
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Biocon Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Biocon  (NSE:BIOCON) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Biocon Cyclically Adjusted PB Ratio Related Terms


Biocon Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Biocon's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocon Cyclically Adjusted PB Ratio Chart

Biocon Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.79 3.60 3.79 4.05 3.47

Biocon Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 3.61 0.00 3.47 0.00

NSE:BIOCON vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Biocon's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocon Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocon's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biocon's Cyclically Adjusted PB Ratio falls into.


NSE:BIOCON
92GF Score
Biocon Ltd NSE:BIOCON
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocon Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Biocon's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Biocon's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/167.3573*167.3573
=0.000

Current CPI (Jun. 2026) = 167.3573.

Biocon Quarterly Data

Book Value per Share CPI Adj_Book
201609 36.841 105.961 58.187
201612 38.567 105.196 61.357
201703 40.314 105.196 64.136
201706 41.002 107.109 64.066
201709 41.161 109.021 63.186
201712 42.193 109.404 64.543
201803 43.173 109.786 65.812
201806 0.000 111.317 0.000
201809 47.530 115.142 69.084
201812 49.383 115.142 71.778
201903 50.817 118.202 71.950
201906 0.000 120.880 0.000
201909 53.171 123.175 72.243
201912 0.000 126.235 0.000
202003 55.882 124.705 74.995
202006 0.000 127.000 0.000
202009 58.788 130.118 75.613
202012 0.000 130.889 0.000
202103 63.558 131.771 80.723
202106 0.000 134.084 0.000
202109 65.698 135.847 80.937
202112 0.000 138.161 0.000
202203 70.678 138.822 85.206
202206 0.000 142.347 0.000
202209 80.698 144.661 93.359
202212 0.000 145.763 0.000
202303 149.641 146.865 170.521
202306 0.000 150.280 0.000
202309 158.731 151.492 175.354
202312 0.000 152.924 0.000
202403 165.304 153.035 180.775
202406 0.000 155.789 0.000
202409 175.286 157.882 185.806
202412 0.000 158.323 0.000
202503 180.658 157.552 191.902
202506 0.000 159.755 0.000
202509 200.765 162.289 207.035
202512 0.000 163.281 0.000
202603 210.137 164.272 214.083
202606 0.000 167.357 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Biocon (NSE:BIOCON) Overvalued in 2026?

Based on GuruFocus' analysis, Biocon stock appears to be overvalued. The current stock price of ₹392.30 is trading 18% above its estimated GF Value™ of ₹332.55. GuruFocus considers Biocon to be Modestly Overvalued.

Key valuation signals for NSE:BIOCON:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: ₹332.55 vs. price of ₹392.30 (18% above fair value)
  • GF Score™: 92/100 with 7 warning signs

No single metric tells the full story. See the NSE:BIOCON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biocon Business Description

Other Exchanges 532523:India
Address 20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560100
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
92GF Score

Get the complete analysis for NSE:BIOCON

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹392.30
Price
₹332.55
GF Value